Results 331 to 340 of about 281,573 (395)

Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

British Journal of Haematology, EarlyView.
We report the UK experience of autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS) in 364 patients. In our observational study, transplant‐related mortality was 1.4%, Epstein–Barr virus reactivation occurred in 75.9%, while disability progression‐free survival was 83.5% at 2 years post‐AHSCT and 62.4% at 5 years.
Majid Kazmi, Paolo A. Muraro, Varun Mehra, Ian Gabriel, Eleonora De Matteis, Gavin Brittain, Alice Mariottini, Richard Nicholas, Eli Silber, Julia Lee, Rachel Pearce, Ruth Paul, Maria Pia Sormani, Alessio Signori, Victoria Potter, Eduardo Olavarria, Ram Malladi, Basil Sharrack, John A. Snowden   +18 more
wiley   +1 more source

Pharmacogenetic Biomarkers of Ibrutinib Response and Toxicity in Chronic Lymphocytic Leukemia: Insights from an Observational Study. [PDF]

Pharmaceuticals (Basel)
Pérez-Gómez N, Sanz-Solas A, Cuevas B, Cuevas MV, Alonso-Madrigal C, Loscertales J, Álvarez-Nuño R, García C, Zubiaur P, Villapalos-García G, Parra-Garcés RM, Mejía-Abril G, Alcaraz R, Vinuesa R, Díaz-Gálvez FJ, González-Oter M, García-Sancha N, Azibeiro-Melchor R, González-López TJ, Abad-Santos F, Labrador J, Saiz-Rodríguez M.   +21 more
europepmc   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

British Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu, Xipeng Yue, Xinrong Zhan, Xiaojuan Liu, Hongxia Ma, Fuli Qin, Lijuan Duan, Hongmian Zhao, Yan Zhang, Shiqiang He, Huifang Zhao, Chunlei Zhang, Xiangke Xin, Wenli Zhang, Yongping Song, Bingcheng Liu, Weiming Li, Yanli Zhang   +17 more
wiley   +1 more source

Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia. [PDF]

Front Cell Dev Biol
Gamal W, Mediavilla-Varela M, Kunta V, Sahakian E, Pinilla-Ibarz J.   +4 more
europepmc   +1 more source

Plasma levels of Human Granulocytic Elastase-alpha-Proteinase Inhibitor Complex (E-alpha1PI) in Leukemia [PDF]

, 1984
Hiller, E., Jochum, Marianne
core  

Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ/CD19 depletion or post‐transplant cyclophosphamide

British Journal of Haematology, EarlyView.
Summary Human leukocyte antigen (HLA)‐haploidentical haematopoietic cell transplantation (haplo‐HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT.
Riccardo Masetti, Davide Leardini, Francesca Gottardi, Francesco Baccelli, Giorgio Antonio Maria Ottaviano, Francesca Vendemini, Francesco Saglio, Filomena Pierri, Mattia Algeri, Francesca Del Bufalo, Pietro Merli, Arcangelo Prete, Simone Cesaro, Marek Ussowicz, Maura Faraci, Marco Zecca, Franca Fagioli, Adriana Balduzzi, Jean‐Hugues Dalle, Franco Locatelli, Daria Pagliara   +20 more
wiley   +1 more source

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells. [PDF]

Blood Adv
Kost SEF, Saleh A, Brown J, Yuan SH, Kuzio B, Yang L, Banerji V, Gibson SB, Johnston JB, Katyal S.   +9 more
europepmc   +1 more source

CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Treatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies. CD123, or the interleukin‐3 (IL‐3) receptor, has long been known as a potential target expressed on AML blasts, and a range of different approaches to targeting CD123 have been trialled with ...
Alexandra Dreyzin, Noa G. Holtzman, Challice L. Bonifant   +2 more
wiley   +1 more source

The importance of systemic inflammatory response measurements as pretransplant risk factors for outcome after allogeneic haematopoietic cell transplantation

British Journal of Haematology, EarlyView.
In oncological patients SIR measures like the mGPS have great impact on prognosis at starting therapy. We recorded at admission for allo‐HCT the mGPS in 2201 patients: score 0 CRP/sALB normal; score 1 CRP >10mg/dl; score 2 CRP >10mg/dl + sALB <35g/L. Multivariate analysis revealed a significant impact with a low GPS score for OS: mGPS 1 vs.
Hartmut Bertz, Jörg Sahlmann, Donald C. McMillan, Claudia Wehr, Jesus Duque‐Afonso, Kristina Maas‐Bauer, Ralph Wäsch, Julia Nikolaychuk, Christine Greil, Jann Arends, Jürgen Finke, Robert Zeiser   +11 more
wiley   +1 more source

A Distinctive Case of Hemophagocytic Lymphohistiocytosis in Chronic Lymphocytic Leukemia. [PDF]

J Investig Med High Impact Case Rep
Jayakumar J, Ginjupalli M, Khan F, Ayyazuddin M, Ashar Ali M, Isaac Coss G, Ullah A.   +6 more
europepmc   +1 more source